Cladribine for

Citric acid, glucono-delta-lactone and mag carbonate for Cladribine for... 

Cladribine (2-Chlordeoxyadenosine) is a synthetic purine nucleoside that is converted to an active cytotoxic metabolite by the deoxycytidine kinase. The drug is relatively selective for both normal and malignant lymphoid cells. 

Cladribine -as therapy for low-grade or mantle cell lymphoma... 

Cladribine 0.09 mg/kg/d for 7 days by continuous IV infusion in sterile saline Myelosuppression, nausea and vomiting, and immunosuppression... 

Cladribine. Cladrihine, Leustatin. 2-CdA, NSC-1050 14-F. 2-chlorodeoxyadcnosine. 2-chloro-2 -deoxy- o-adenosine. is prepared by a multistep procedure from 2.8-dichloroudcnine and o-xylo.sc, and i.s supplied as a I mg/ mL sterile solution in 0.9% Sodium Chloride for Injection, USP. The desired dose is removed from the vial and diluted with normal. saline for infusion over 24 hours. Thc.se solutions arc stable for 72 hours. Infusion is continued for 5 to 7 days. 

Cladribine (2-chlorodeoxyadenosine 2-CDA) is a purine nucleoside analog that is resistant to inactivation by adenosine deaminase. The triphosphate form of this agent is incorporated into DNA, resulting in inhibition of DNA synthesis and early chain termination. Cladribine s antitumor activity is unusual for an antimetabolite in that it affects both actively dividing and resting cancer cells. Like fludarabine, cladribine possesses immunosuppressive effects that place patients at risk for serious opportunistic infections. ... 

Hsieh, Y. et al., Comparison of fast liquid chromatography/tandem mass spectrometric methods for simultaneous determination of cladribine and clofarabine in mouse plasma, J. Pharm. Biomed. Anal., 44(2), 492, 2007. 

Cladribine, a purine nucleoside analog, with antineoplas-tic properties (0.09 mg/kg daily by continuous IV infusion for 7 days), is indicated in the treatment of active hairy cell leukemia. In addition, it has been used in advanced cutaneous T-cell lymphomas, chronic lymphocytic leukemia, non-Hodgkin s lymphomas, acute myeloid leukemias, autoimmune hemolytic anemia, mycosis fungoides, or Sezary syndrome (see also Figure 15). 

Global immunosuppression with azathioprine and cyclophosphamide has been ntilized with varying benefits for several decades. In addition, there have been recent reports of beneficial effects of immnnosnppressive agents such as methotrexate and cladribine in patients with chronic progressive MS. 

---